MENU

CSL pushes profits up 19% for 2013

Biopharmaceutical company CSL  (ASX: CSL) reported full year earnings today, and the diagnosis is good.

On the top line, CSL saw sales improve 7% to $5.0 billion. And while revenue headed higher, the company managed to move up its bottom line even further. As EBIT margins grew 2.5 points to 29.1%, EBIT grew 17% to $1.49 billion. The company seems to be doing a better job on its tax report, too, with after-tax net profit up 19%. For investors, all this simmers down to $2.44 EPS, a 24% improvement over 2012’s numbers.

“This is an excellent result and reflects the combined effort of many people across the Company, in particular our immediate past Chief Executive Officer, Dr Brian McNamee,” said new CEO Paul Perrault in a statement today. “The Company’s core products of immunoglobulin and albumin have performed very well and we have strengthened our margins through a change in sales mix and a relentless pursuit of efficiency. Our suite of specialty products grew strongly, supported by the registration in the US of Kcentra, a product used in the urgent reversal of anticoagulant warfarin in patients with acute major bleeding.”

With cash flow from operations up 9%, CSL isn’t taking any short-term shortcuts on its profit prognosis. R&D expanded 16% to $427 million, a sign that the company’s looking out for long-term shareholders. CSL also managed to increase its total 2013 dividends 18% to $1.02.

Shares of CSL are up 4.0% as of this writing, but there’s another dividend stock you need to check out today. Discover The Motley Fool’s favourite income idea for 2013-2014 in our brand-new, FREE research report, including a full investment analysis! Simply click here for your FREE copy of “The Motley Fool’s Top Dividend Stock for 2013-2014.”

More reading


Motley Fool contributor Justin Loiseau has no position in any stocks mentioned in this article. You can follow him on Twitter @TMFJLo.

The 5 mining stocks we’re recommending in 2019…

For decades, Australian mining companies have minted money for individual investors like you and me. But if you believe the pundits and talking heads on TV, those days are long gone. Finito! Behind us forever…

We say nothing could be further from the truth. To earn the really massive returns, you’ve got to fish where others aren’t fishing—and the mining sector could be primed for a resurgence. That’s why top Motley Fool analysts just revealed their exciting new research on 5 ASX miners they believe could help you profit in 2019 and beyond…

Including:

The best way we see to play the global zinc shortage… Our #1 favourite large-cap miner (hint: it’s not BHP)… one early-stage gold miner we think could hit the motherlode… Plus two more surprising companies you probably haven’t heard of yet!

For free access to our brand-new research, simply click here or the link below. But be warned, this research is available free for a limited time only, and we reserve the right to withdraw it at any time.

Click here for your FREE report!